Philippe Moreau - Biography#

Philippe Moreau (DOB 29-04-1963) serves as Professor of Clinical Hematology at the University Hospital of Nantes, France.

Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is president of International Myeloma Society (IMS) since 2023, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He is a member of the French cooperative group IFM (Intergroupe Francophone du Myélome) and was the chairman of this group from 2006 to 2009 and from 2020 to 2023.

In the last 20 years, he has served as the principal investigator of several phase 2 and phase 3 international clinical trials (academic or company sponsored studies) leading to the approval by EMA and FDA of Bortezomib, Carfizomib, Ixazomib, Pomalidomide, Daratumumab, Isatuximab, or more recently Teclistamab.

His research is widely published, with more than 500 peer-reviewed articles and reviews or guidelines that have appeared in high impact factor journals including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, and Blood. His h-index is 157 (108177 citations). He has been listed into the Clarivate Analytics (2017-2023), list of world-class highly cited researchers, that rank in the top 1% by citations for field and year in Web of Science, and he is at the first rank of the world’s expertise in multiple myeloma (https://expertscape.com/ex/multiple+myeloma), based on 20,309 eligible articles published since 2013.

He is frequently invited speaker at international hematologic oncology meetings, and during Educational Session on Multiple Myeloma at ASH, ASCO or EHA.

Professor Moreau received in 2018 the prestigious Robert A. Kyle lifetime achievement award.